The discussion on the merger of NLS Pharmaceutics and Kadimastem have been concluded, with the companies forming a new combination company called Newcelx. The new company is focusing on the development of cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, integrating regenerative medicine and neuroscience expertise within a unified platform. .

关于NLS Pharmaceutics和Kadimastem合并的讨论已经结束，两家公司成立了一家名为Newcelx的新组合公司。新公司专注于开发基于细胞和小分子疗法，用于治疗神经退行性疾病和代谢疾病，并在一个统一平台上整合了再生医学和神经科学的专业知识。

NewcelX Ltd. (NASDAQ:

新赛尔X有限公司（纳斯达克：

NCEL

北卡罗来纳州电力合作社 (NCEL)

) is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. .

）是一家生物技术公司，致力于开发基于细胞和小分子的变革性疗法，用于治疗神经退行性疾病和代谢性疾病。该公司的一体化平台结合了先进的干细胞技术和神经科学专业知识，提供可扩展的再生治疗方案，针对肌萎缩侧索硬化症（ALS）和1型糖尿病等疾病。

NewcelX is a result of a merger between NLS Pharmaceuticals, a Swiss clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders and

NewcelX 是瑞士临床阶段生物制药公司 NLS Pharmaceuticals 与另一家公司合并的结果，该公司专注于开发中枢神经系统疾病疗法。

Kadimastem Ltd

凯迪玛斯特姆有限公司

., a clinical-stage cell therapy company developing treatments for ALS and diabetes. The formed company is headquartered in Zurich, with research and development operations in Ness Ziona, Israel—led by the leadership of NLS and Kadimastem, including Ronen Twito as Executive Chairman and Chief Executive Officer. .

一家临床阶段的细胞治疗公司，致力于开发ALS和糖尿病的治疗方法。公司总部位于苏黎世，在以色列内斯齐奥纳设有研发业务，由NLS和Kadimastem的领导层带领，包括执行主席兼首席执行官罗南·特维托。

Pursuant to the Merger Agreement, the holders of Kadimastem ordinary shares outstanding immediately prior to the Merger received 0.706 NewcelX common shares in exchange for each Kadimastem ordinary share in the Merger. The exchange ratio also reflects the 1-for-10 reverse share split effected by NewcelX in connection with the Merger.

根据合并协议，合并前立即持有Kadimastem普通股的股东在合并中每股Kadimastem普通股获得了0.706股NewcelX普通股。该兑换比率还反映了NewcelX在合并过程中实施的1比10的反向股票分割。

Following completion of the Merger, NewcelX has approximately (i) 4,558,378 common shares, par value CHF 0.05 issued and outstanding, (ii) 1,060,574 total outstanding common shares, par value CHF 0.05, issuable upon the exercise of pre-funded warrants issued as Merger consideration, (iii) 13,778 preferred shares, par value CHF 0.05 issued and outstanding, and (iv) 58,320 preferred participation certificates, par value CHF 0.05 issued and outstanding..

合并完成后，NewcelX 共有以下发行在外的股份：(i) 约4,558,378股面值为0.05瑞士法郎的普通股；(ii) 1,060,574股面值为0.05瑞士法郎的普通股，可通过行使作为合并对价发行的预融资权证获得；(iii) 13,778股面值为0.05瑞士法郎的优先股；以及(iv) 58,320份面值为0.05瑞士法郎的优先参与证书。

“This merger unites years of pioneering science in cell therapy and drug discovery under one global platform,” said Prof. Michel Revel, Chief Scientific Officer of NewcelX. “NewcelX represents the next step in realizing the promise of regenerative medicine for patients living with amyotrophic lateral sclerosis ('ALS'), diabetes, and other neurodegenerative diseases.”.

“这次合并将多年在细胞治疗和药物发现方面的开创性科学成果汇聚在一个全球平台上，”NewcelX 首席科学官米歇尔·雷维尔教授表示。“NewcelX 代表了实现再生医学对肌萎缩侧索硬化症（‘ALS’）、糖尿病和其他神经退行性疾病患者的承诺的下一步。”

Ronen Twito, Executive Chairman and Chief Executive Officer of NewcelX said, “With the launch of NewcelX, we have brought together exceptional science and a global leadership team with the potential to change lives. The completion of the merger and the commencement of trading on Nasdaq mark a significant milestone that reflects the trust and confidence of our shareholders and investors, and I am deeply grateful for their support as we take this next step forward together.

纽赛尔公司的执行主席兼首席执行官罗南·特维托表示：“随着纽赛尔的成立，我们汇聚了卓越的科学成果和具有改变生命潜力的全球领导团队。此次合并的完成以及在纳斯达克开始交易标志着一个重要的里程碑，反映了我们的股东和投资者的信任与信心，对于我们共同迈出的这一步，我深表感激。”

We are now preparing to initiate our Phase 2a clinical trial of AstroRx™ in ALS and to advance the development of IsletRx™ for the treatment of Type 1 diabetes without the need for lifelong immunosuppression.”.

我们正在准备启动AstroRx™在ALS中的IIa期临床试验，并推进IsletRx™的开发，以在无需终身免疫抑制的情况下治疗1型糖尿病。

(Press release/RAN)

（新闻稿/随机接入网络）

0

0

Comments

评论

Back to all news

返回所有新闻

Please

请

login

登录

or

或

sign up

注册

to comment.

评论。

Commenting guidelines

评论指南

Send

发送